The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Verona Pharma Amends Strategic Financing with Oaktree and OMERS
Mar 28, 2025•about 1 year ago
Contract Type
partnership
LondonBiotechnology Research
Description
Verona Pharma plc has amended its strategic financing by repaying the revenue interest purchase and sale agreement (RIPSA) and increasing the debt facility to $450 million with funds managed by Oaktree Capital Management, L.P. and OMERS Life Sciences. The amendment provides the company with increased financial flexibility and simplifies its balance sheet, with access to an additional $200 million under the term loan facility.
Company Information
Company
Verona Pharma
Location
London, England, United Kingdom
About
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for respiratory diseases. The company's lead product candidates target conditions such as chronic obstructive pulmonary disease (COPD) and asthma. Verona Pharma is committed to addressing significant unmet medical needs in respiratory care. Its team combines expertise in drug development and commercialization.
Predictive Intelligence
Strategic
ML-powered predictions for Verona Pharma's next move
LondonBiotechnology Research